Rappta Therapeutics Oy has divulged protein phosphatase 2A (PP2A) activators reported to be useful for the treatment of cancer, diabetes, neurodegeneration, heart failure, cardiac hypertrophy, autoimmune, chronic obstructive pulmonary and nonalcoholic fatty liver diseases among others.